March 2024
1. KANKASA C, Mennecier A, Sakana BLD, Moles JP, et al
   Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.
   Lancet. 2024 Mar 11:S0140-6736(23)02464-9. doi: 10.1016/S0140-6736(23)02464.
   

   >> Share

   
   December 2023
2. PAPINENI P
   Directly observed therapy.
   Lancet. 2023;400:2265-2266.
   

   >> Share

   
   June 2023
3. HUANG C, Huang L, Wang Y, Li X, et al
   6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
   Lancet. 2023 Jun 12:S0140-6736(23)00810-3. doi: 10.1016/S0140-6736(23)00810.
   

   >> Share

   
   October 2022
4. WONG CKH, Au ICH, Lau KTK, Lau EHY, et al
   Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kon
   Lancet. 2022;400:1213-1222.
   

   >> Share

   
   May 2022
5. 
   Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
   Lancet. 2022 May 2. pii: S0140-6736(22)00519.
   

   >> Share

   
   April 2022
6. DELANY-MORETLWE S, Hughes JP, Bock P, Ouma SG, et al
   Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
   Lancet. 2022 Apr 1. pii: S0140-6736(22)00538.
   

   >> Share

   
   March 2022
7. WATERS L, Marra F, Pozniak A, Cockburn J, et al
   Ritonavir and COVID-19: pragmatic guidance is important.
   Lancet. 2022 Mar 22. pii: S0140-6736(22)00280.
   

   >> Share

   
   February 2022
8. USHER AD
   The global COVID-19 treatment divide.
   Lancet. 2022;399:779-782.
   

   >> Share

   
   
9. SIVA N
   Gilead and ViiV Healthcare reach settlement over HIV drug.
   Lancet. 2022;399:618.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share